Johnson & Johnson Says 50% Of Patients Progression-Free At Five Years After Single Carvykti Infusion In Phase 2 Multiple Myeloma Trial

Loading news article.

Johnson & Johnson Says 50% Of Patients Progression-Free At Five Years After Single Carvykti Infusion In Phase 2 Multiple Myeloma Trial | WAPE

Article summary